Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx Biosciences (INBX) will present studies of ordastobart and ozekibart at upcoming scientific conferences, beginning October 25, 2026.

Rhea-AI Summary

Inhibrx Biosciences (INBX) will present studies of ordastobart and ozekibart at upcoming scientific conferences, beginning October 25, 2026.

The ESMO Congress in Madrid will feature the phase 2 primary analysis of HexAgon-HN, studying ordastobart with pembrolizumab in head and neck cancer. The MSTS Annual Meeting in Miami on October 29 will cover secondary efficacy endpoints from the phase 2 ChonDRAgon study of ozekibart in conventional chondrosarcoma. At CTOS in Seoul, a November 19 poster will address ozekibart with irinotecan and temozolomide in Ewing sarcoma; a November 20 oral presentation will cover ChonDRAgon subgroup analysis and updated progression-free survival, the time patients live without disease worsening.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:

2026 European Society for Medical Oncology (ESMO) Congress
October 25^th, 2026 – Madrid, Spain

Title: HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1–high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)—phase 2 primary analysis
Format: Oral Presentation
Lead Author: Jong Chul Park
Date and Time: Sunday, October 25^th, 2026; 8:30-10:00 AM CET

2026 Musculoskeletal Tumor Society (MSTS) Annual Meeting
October 29^th, 2026 – Miami, Florida

Title: The Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Secondary Efficacy Endpoints from the Randomized, Registrational, Phase 2 ChonDRAgon study
Format: Oral Presentation
Lead Author: Robin Jones
Date and Time: Thursday, October 29^th, 2026; 2:50-3:40 PM EST

2026 Connective Tissue Oncology Society (CTOS) Annual Meeting
November 19^th – 20^th, 2026 – Seoul, South Korea

Title: Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Subgroup Analysis and Updated Progression-Free Survival (PFS) from the Randomized, Phase 2 ChonDRAgon Study
Lead Author: Sant Chawla
Format: Oral Presentation
Date and Time: Friday, November 20^th, 2026; 11:00 AM-12:30 PM KST

Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
Lead Author: Varun Monga
Format: Poster Presentation
Date and Time: Thursday, November 19^th, 2026; 5:30-6:30 PM KST

The presentations and poster will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations, upon commencement of each event.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and ordastobart (INBRX-106), both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-conferences-302907553.html

SOURCE Inhibrx Biosciences, Inc.